Valuation : NetraMark Holdings Inc.

Market Cap 66.24M 48.08M 41.34M 38.89M 35.49M 4.56B 66.58M 461M 178M 2.33B 181M 177M 7.41B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 66.24M 48.08M 41.34M 38.89M 35.49M 4.56B 66.58M 461M 178M 2.33B 181M 177M 7.41B EV / Sales 2026 *
165x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
1 day-7.88%
1 week-7.88%
Current month-7.88%
1 month-26.15%
3 months-32.09%
6 months-36.75%
Current year-49.89%
1 week 0.4
Extreme 0.3985
0.4
1 month 0.4
Extreme 0.3985
0.51
Current year 0.4
Extreme 0.3985
0.89
1 year 0.4
Extreme 0.3985
1.15
3 years 0.11
Extreme 0.114
1.26
5 years 0.1
Extreme 0.1045
1.61
10 years 0.1
Extreme 0.1045
1.61
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-7.88%-7.88% - - 44.54M
Average -7.88%
Weighted average by Cap. -7.88%

Financials

2026 *2027 *
Net sales 401K 291K 250K 235K 215K 27.59M 403K 2.79M 1.08M 14.1M 1.09M 1.07M 44.88M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!